| Sign In to gain access to subscriptions and/or personal tools. |
The Therapeutic Role of Incretin Mimetics and DPP-4 InhibitorsFrom the University of Michigan Medical School, Ann Arbor, Michigan Correspondence to Martha M. Funnell, MS, RN, CDE, Michigan Diabetes Research and Training Center, 300 North Ingalls Street, 3Do6, Box 0489, Ann Arbor, MI, 48109-0489 (mfunnell{at}umich.edu) Purpose Gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) stimulate the secretion of insulin when blood glucose levels are elevated and inhibit the postprandial release of glucagon. An increased understanding of the role of these incretin hormones in insulin and blood glucose regulation has resulted in the development of new types of medications for managing diabetes. GLP-1 agonists and dipeptidyl peptidase-IV (DPP-4) inhibitors are 2 classes of medications that have been shown to offer benefits for patients with type 2 diabetes. To use and teach patients how to use these medications effectively, educators need to understand their mechanisms of action, indications and contraindications, side effects, and effectiveness. Expanding the number of options available has increased the complexity of providing care and education, but also offers new opportunities to help our patients achieve better outcomes. Conclusion This article provides an overview of the physiology of insulin regulation and the roles of GIP, GLP-1, and DPP-4; discusses how the action of incretin hormones is affected by diabetes; and describes the therapeutic agents in these classes and their potential use by people with diabetes.
The Diabetes Educator, Vol. 35, No. Supplement 1,
12S-17S (2009) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
